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Objectives: The aim of this study was to assess the accuracy of the English National Horizon Scanning Centre (NHSC) in identifying and filtering pharmaceutical developments using end user and
international collaborator databases of emerging technologies as proxies for new drugs of likely significance to health services and/or patients.
Methods: We used the NHSC information system and the list of National Institute for Health and Clinical Excellence (NICE) technology appraisals to estimate the false positive rate for NHSC
identification, filtration, and reporting. We assessed the sensitivity of NHSC identification and filtration of pharmaceuticals for NICE technology appraisals from 1999 to the end of December 2010,
and for pharmaceuticals entered into the EuroScan International Network database.
Results: We estimate that overall NHSC identification, filtration and reporting had a positive predictive value of 0.39 (95 percent CI, 0.36 to 0.43) and a false positive rate of 60 percent. Using NICE
appraisals and EuroScan’s database as proxies for pharmaceuticals of significance, we estimate the NHSC sensitivity over the 10-year period at 0.92 (95 percent CI, 0.89 to 0.95) and 0.89 (95
percent CI, 0.82 to 0.96) respectively.
Conclusions: Our results suggest that the NHSC has performed well in terms of sensitivity over the past decade, but that the false positive rate of 60 percent may indicate that the filtration criteria for
pharmaceuticals could be tightened for increased efficiency. Future evaluations of EAA systems should include an element of external review and explore the level of accuracy acceptable to funders and
customers of such systems.
Keywords: Horizon scanning, Early awareness and alert systems, Healthcare technology, Program effectiveness
Many countries have established systems to support the uptake
of new and emerging health technologies. TheNational Horizon
Scanning Centre (NHSC) in England is one such early aware-
ness and alert (EAA) system, and provides advance notice of
new and emerging health technologies and interventions that are
likely to have a significant impact on theEnglishNationalHealth
Service (NHS) and/or patients, within the next 2 to 3 years (5;8).
The work of the NHSC informs the future work program of the
National Institute for Health and Clinical Excellence (NICE),
the Health Technology Assessment (HTA) program and other
national policy- and decision-making organizations.
The NHSC
The NHSC was established as an independent research team
at the University of Birmingham in April 1998 and incorpo-
rated as a research program within the United Kingdom’s Na-
tional Institute for Health Research (NIHR) in 2006. The Cen-
tre has increased significantly in size since 1998 from six to
twenty-one whole-time staff with an annual budget of around
£1.8M in 2010/11 (US$2.9M; €2.05M). The Supplementary
Table 1, which can be viewed online at www.journals.
cambridge.org/thc2012035, sets out the principal features
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of the Centre and its methods (available at www.journals.
cambridge.org/thc).
Key features of the NHSC methods include, in addition
to routine scanning of media and other information sources,
collaboration with clinical and technology experts and expert
groups, and extensive and proactive contact with commer-
cial companies to identify products in company development
pipelines. In addition to its routine scanning and company con-
tacts program, the NHSC undertakes technology- and disease-
specific reviews to ensure all clinical areas are scrutinized over
time; to focus on areas with known multiple or complex devel-
opments, or on areas of particular customer interest; and/or on
patient groups with significant or unmet needs.
Public NHSC outputs include short technology briefings
and news briefs written using information provided by the com-
pany and a defined search of the internet. Other outputs include
short confidential filtration forms on emerging pharmaceuticals
that are used by customers for initial filtration, and reports from
the technology- and disease-specific reviews. The NHSC does
not undertake a detailed assessment of any technology or make
recommendations for coverage within the health service.
NHSC technology briefings on emerging pharmaceuticals
directly enter the decision-making process at NICE and the Ad-
visory Group for National Specialized Services (AGNSS), a
group that commissions services for people with very rare dis-
orders. The context for health service decision making around
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medical devices and diagnostics is much less clear cut, and
NHSC news briefs are for wider readership, rather than enter-
ing directly into a national decision-making process.
In addition to its main function, the NHSC undertakes re-
search into the development,marketing, diffusion, and impact of
new technologies; and the evaluation and development of EAA
system processes, methods and outputs. The NHSC is also host
to the Secretariat of the International Information Network on
New and Emerging Health Technologies (the EuroScan Inter-
national Network) and a member of the International Network
of Agencies for Health Technology Assessment (INAHTA).
Evaluation of Early Awareness and Alert Systems
Although EAA systems have been in place for several years,
there has been little published on the efficiency of core meth-
ods, for example, identification, filtration, prioritization, and
reporting; or the overall system effectiveness or impact on pol-
icy decisions or technology diffusion.
Simpson et al. piloted a method normally applied to deter-
mine the accuracy of diagnostic tests to estimate the sensitivity
and specificity of the NHSC selection and prioritisation process
in its first 5–6 years (7). The authors estimated that the NHSC
prioritisation had a high negative 0.98 (95 percent confidence
interval (CI), 0.92–0.99) and a low positive predictive value
0.14 (95 percent CI, 0.06–0.3); with a sensitivity of 0.71 (95
percent CI, 0.36–0.92) and specificity of 0.73 (95 percent CI,
0.64–0.8).
Douw and Vondeling used a similar method to assess the
completeness of identification and accuracy of impact predic-
tions made by oncologists about new anticancer drugs that may
impact on Danish health care over the next 5 years (1). Results
showed that experts were poor at identifying new anticancer
drugs (sensitivity 0.63; 95 percent CI, 0.31–0.86), but were
good at predicting which drugs were (positive predictive value
1.0; 95 percent CI, 0.57–1.0) and were not (negative predictive
value 0.79; 95 percent CI, 0.52–0.92) likely to have an impact
on health care in the future.
Murphy et al. used a Delphi-type process with members of
the EuroScan International Network to develop a shared under-
standing of the important characteristics and components of an
effective EAA system (4). The characteristics and components
identified as being important for system effectiveness almost all
related to structure and process items, with only three related to
outcomes.
Packer et al. studied the international diffusion of six new
health technologies across 10 developed countries and evalu-
ated the association between diffusion and variables including
the presence or absence of early awareness andHTA activity (6).
This research found that early awareness and HTA activity, and
the presence of a “fourth hurdle” (the requirement to demon-
strate clinical- and cost-effectiveness in addition to safety, qual-
ity and efficacy) play some part in influencing diffusion of new
health technologies. Mundy et al., however, compared the Aus-
tralian pharmaceutical approval and regulatory system (which
does not have associated EAA activity) with that of the United
Kingdom and Canada (which do have systems to identify phar-
maceuticals in development). They concluded that the value of
EAA activity is dependent on the systems it is trying to support
and that, due to the nature of the system already in place in
Australia, an EAA system would neither improve access to new
pharmaceuticals nor better inform decision makers (3).
Oneway of assessing the identification and filtration aspects
of a system is to ask if any technologies produced a significant
impact on patients and/or health services without first being
identified and reported by the EAA system, that is, the system’s
sensitivity. However, such an evaluation requires identification
of all new technologies deemed to have had a significant im-
pact on patients and health services, before scrutiny of the EAA
system outputs. A major problem with this approach is that the
value of a technology is not absolute and will be interpreted dif-
ferently within separate healthcare systems and between health
professionals and patients.
Within England, NICE provides guidance to the NHS in
England and Wales on the clinical and cost effectiveness of se-
lected new and established technologies. Pharmaceutical topics
for technology appraisal come from several sources in addition
to the NHSC, including health professionals, the general public,
and the Department of Health’s national clinical directors and
policy teams. It is therefore possible that if the NHSC did not
notify NICE of a key pharmaceutical that was thought to have
potential orwas impacting significantly on patients or health ser-
vices, the drug could be notified to NICE from another source
and guidance developed. The list of topics appraised by NICE
could therefore be used as a proxy for a list of technologies with
the potential for significant impact. A second source that could
be thought of as a proxy, or at least a comparative source, is
the database of new and emerging health technologies of the
EuroScan International Network (http://www.euroscan.org.uk).
Member agencies are encouraged to enter technologies that
they have identified. Although identification and filtration crite-
ria and methods differ between agencies, technologies entered
are likely to be those with the potential for greater impact than
those not identified and entered on the database.
Another approach to assessing the identification and filtra-
tion aspects of a system is to estimate the proportion of topics of
no significance to patients or health services that were reported
to customers—the system’s specificity. Estimation of specificity
requires an estimate of the total number of new drugs and new
clinical indications for licensed products launched in England
over the relevant time period.UsingNICE technology appraisals
as a proxy for significance to patients and health services, we
could then estimate the number of topics launched of little or
no significance. However, although it is possible to find out
how many licenses to market have been granted from the Euro-
peanMedicines Agency (EMA), some products granted a Euro-
pean license will not be launched in England, and many license
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Table 1. Topics Not Reported by the NHSC to NICE, or Not Input Into the EuroScan International Network Database
NICE EuroScan
proxy proxy
Not in NHSC remit and/or not in filtration criteria at the time of identification proxy proxy
Not identified – but not in NHSC remit, e.g., social care, preventive vaccines, food supplements 0 4
Not identified – but unlikely to have fitted filtration criteria at the time e.g. not in remit, not new, ‘me-toos’ in the early years of
NHSC activity.
22 + 2∗ 17
Identified – but not in NHSC filtration/prioritisation criteria at the time e.g. not in remit, not new, ‘me-toos’ in the early years of
NHSC activity.
1 7
Topics potentially missed by NHSC
Not identified – but should have been (potentially within remit and would have met filtration criteria at the time; potential topic
we should/would have written at the time).
18 + 3∗ 8
Identified – but not selected by NHSC filtration. But perhaps should have been selected in retrospect. 0 + 1∗ 1
Identified – but not thought to be innovative (filtered out). But perhaps was innovative in retrospect. 0 0
TOTAL 44 37
∗Three topics required two separate codes for completeness. These were appraisals of multiple drugs, some of which the NHSC had identified, others that had
not been; and some identified products that would have fitted filtration criteria and others that would not have done.
variations relate to minor changes to current indications rather
than wholly new clinical indications. The number of licenses
granted will therefore be an overestimate of the number of new
products or clinical indications launch in the England, poten-
tially increasing any estimates of system specificity. Other mea-
sures of accuracy include positive predictive value and negative
predictive value. Given the comments above we will not be able
to estimate negative predictive value in this evaluation.
In this study, we assess the accuracy of the NHSC in iden-
tifying and filtering pharmaceutical developments using NICE
pharmaceutical technology appraisal topics and EuroScan In-
ternational Network database entries as proxies for new drugs
of key significance.
METHODS
We used NHSC information systems to identify technology
briefings sent for consideration of NICE technology appraisal
from 1998 to the end of December 2010. We then downloaded
a list of all NICE technology appraisals published, currently in
development, or proposed until the end of December 2010, from
NICE’s Web site (http://www.nice.org.uk/). For the estimation
of sensitivity around pharmaceutical topics, we excluded tech-
nology appraisals of nonpharmaceuticals and reviews of previ-
ous appraisals unless a new drug was included in the review, but
included topics that were subsequently discontinued. We cross-
checked the final list with NHSC outputs to determine whether
the NHSC had reported on each new drug before the topic was
referred to NICE for appraisal. Appraisal topics without a prior
NHSC output were scrutinized independently by CP and MF
using an agreed framework to determine why the NHSC had
not informed NICE (Table 1). Any discrepancies between the
authors were discussed and agreement reached.
We downloaded all pharmaceutical topics entered onto the
EuroScan International Network database between 1 January
2001 and 31 December 2010 from all member agencies except
theNHSC. Each entrywas cross checked against theNHSC’s in-
ternal database to determine whether the NHSC had previously
identified the topic. EuroScan International Network database
topics that the NHSC had not previously identified were coded
independently by CP and MF using the same framework with
reconciliation as before.
RESULTS
Since 1998, the NHSC has produced around 950 technology
briefings and summaries which entered the prioritisation pro-
cesses for NICE appraisals (752 topics) or for consideration by
the NHSC’s other customers. Of these 295 were products (drugs
and non-drugs) that were eventually referred to NICE for ap-
praisal; a positive predictive value of 0.39 (95 percent CI, 0.36
to 0.43) and a false positive rate of 60 percent. Just under 80
percent of the NHSC briefings have related to emerging drugs,
the majority of which have been in the cancer field.
NICE Appraisals
We identified 291 NICE appraisals and reviews of appraisals
of pharmaceuticals from the NICE Web site to the end of De-
cember 2010; with 157 completed appraisals, 116 appraisals in
development, and 18 proposed topics. We identified 44 topics
without a correspondingNHSC output (table 1). In twenty-three
instances, we judged that that the topic would not have fitted the
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EuroScan Internaonal Network 
database entries 
NICE appraisal topics
Abciximab for coronary artery disease 2001 Temozolomide for brain cancer
2002
Lumiracoxib for pain management
Parecoxib sodium for peri-operave pain 
relief
2003
Insulin aspart for control of hyperglycemia 
in adults
2004
Pregabalin for peripheral neuropathic pain 2005
Clopidogrel and dipyridamole for vascular 
disease (replaced by TA 210)
Immuno-suppressive regimens for renal 
transplantaon (children and adolescents)
2006
Peginterferon alfa and ribavirin for 
hepas  C
Hormonal treatments for breast cancer 
(early)
Yrium-90 microspheres for unresectable 
hepatocellular carcinoma
2007 Fludarabine for leukaemia (lymphocyc)
2008
Agents for the primary prevenon of 
osteoporosis
2009
Geﬁnib for lung cancer (non-small-cell, 
second line) (terminated appraisal)
Coleselelam for heterozygous familial 
hypercholesterolemia in children  (10-17 
years)
2010
Human growth hormone for growth 
hormone deﬁciency (adults)
Atypical anpsychocs for schizophrenia
Clopidogrel for acute coronary syndromes
Immuno-suppressive regimens for renal 
transplantaon (adults)
Geﬁnib for lung cancer (non-small-cell, 
ﬁrst line)
Peginterferon alfa and ribavirin for 
hepas C
Paricalcitol for hyperparathyroidism
Infra-arcular hyaluronic acid for knee 
osteoarthris
Figure 1. Timeline of topics not reported by the NHSC using NICE appraisal topics and EuroScan International Network entries. Note: Five additional NICE appraisals are either discontinued (and therefore do not have a
publication date) or did not have a publication date at the time we undertook the study.
NHSC remit or filtration criteria used at the time, leaving 268
relevant topics. In eighteen instances, we judged that the topics
would or should have passed the filtration step at the time, and
were, therefore, truly missed. There were also three cases where
dual codes were needed, and each of these included a missed
topic code. Overall we judged that the NHSC had potentially
missed twenty-one (7.8 percent) of relevant topics appraised by
NICE, a sensitivity of 0.92 (95 percent CI, 0.89 to 0.95).
EuroScan International Network Database
We identified 108 unique pharmaceutical topics entered onto the
EuroScan International Network database from agencies other
than the NHSC to the end of December 2010. Of these, we
identified thirty-seven topics without a corresponding NHSC
output (Table 1). In twenty-eight instances we judged that the
topic would not have fitted the NHSC remit or filtration criteria
used at the time. In the remaining nine instances (11.3 percent)
we judged that the topics would or should have passed the
filtration step at the time, and were, therefore, missed by the
NHSC, a sensitivity of 0.89 (95 percent CI, 0.82 to 0.96).
The topics not reported by the NHSCwere spread across the
decade (Figure 1). Three of the topics were licensed for use very
soon after the NHSC was established, and it would have been
impractical given the set up time and the relatively small team
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to have expected the fledgling NHSC to pick up these “current”
topics. Two additional NICE appraisal topics were of multiple
drugs of multiple indications in one appraisal topic. The NHSC
had identified at least one of the new drugs and/or indications
in each case, but not all the products and indications considered
in the appraisal.
DISCUSSION AND CONCLUSIONS
Summary of Results
We estimate that NHSC reporting to NICE, for both pharma-
ceutical and nonpharmaceutical topics, had a positive predic-
tive value of 0.39 (95 percent CI, 0.36 to 0.43). Meaning that
almost 40 percent of topics reported to NICE were later se-
lected for NICE technology appraisal and 60 percent were not.
Using NICE appraisals and EuroScan’s database as proxies for
pharmaceuticals of significance, the NHSC did not report on
7.8 percent and 11.3 percent of technologies that it could or
should have identified according to its filtration and prioriti-
zation criteria over a 10-year period; sensitivities of 0.92 (95
percent CI, 0.89 to 0.95) and 0.88 (95 percent CI, 0.82 to 0.96),
respectively.
Strengths and Weaknesses of the Study
In an ideal world, researchers would be able to evaluate the
effectiveness of an EAA system as a whole, rather than eval-
uating individual aspects of the methods such as identification
and filtration. However, there is no such method available and,
as the NHSC neither evaluates the technologies it identifies nor
issues recommendations to the health service, such methodol-
ogy may not be relevant in the context within which the NHSC
works. A major weakness in the study is that the authors are
employed within the NHSC and have been intimately involved
in all aspects of the identification, filtration and reporting of
emerging technologies to the NHSC customers. This is likely
to have introduced some bias, at the very least in interpretation
of the results. It would be a positive step for an independent
evaluation of an EAA to be undertaken.
A weakness of the sensitivity method used is in the se-
lection of proxy measures of the technologies that have made
a significant impact on the English health service and/or pa-
tients. Is the list of technologies selected for appraisal by NICE
or identified by the EuroScan International Network members
a good proxy for technologies having a significant impact on
health services or patients? As the NHSC is funded to identify
and report on emerging drugs of relevant to the English health
service, the list of NICE appraisals is likely to be a better proxy
than international activity.
NICE
As any manufacturer, health professional or patient can suggest
topics for NICE to consider for appraisal and the development
of guidance, we suggest that any topics of likely or actual signif-
icance could be input independently into the system. However,
it is possible that this is not a safe hypothesis, and the list of
important topics may be much wider than the list of NICE tech-
nology appraisals. Indeed, depending on the perspective taken,
it is highly likely that individuals will believe that many more
new technologieswere of importance thanNICE selected for ap-
praisal. Although the NHSC may have identified some of these,
in this situation we have no easy dataset to compare NHSC
activity to.
We also know a small number of topics each year have been
identified by the NHSC but not referred to NICE for appraisal,
but instead notified to the NICE guidelines development teams
for inclusion inNICEguidelines. Some of thesemay be topics of
significance but will not have been captured in the denominator
of our comparison.
Given that the NHSC did not identify or select twenty-
one emerging drugs for notification to NICE for appraisal,
the NHSC’s identification processes may have been insufficient
and/or the filtration criteria used may have been too selective.
The methods used at both these steps have changed signifi-
cantly over the years, and the NHSC has widened its scope and
broadened its identification sources. It will be interesting to see
whether an even greater proportion of future NICE appraisal
topics originate from NHSC activities.
EuroScan
As stated earlier the EuroScan International Network database
may not be a suitable proxy for pharmaceuticals likely to impact
on the English health service, as thosemember agencies that un-
dertake identification work for pharmaceuticals have differing
identification and filtration remits, time frames, and funding. If
the agencies’ time frames are shorter (i.e., products are nearer to
licensing at reporting) than the NHSC, then you would not ex-
pect them to identify emerging drugs before the NHSC, which
tries to identify emerging drugs at around 24–30 months before
licensing and launch. In this case, this dataset would not be a
robust proxy. Additionally, as the NHSC is a major contributor
of emerging pharmaceuticals to the EuroScan database, other
member agencies who identify emerging pharmaceuticals may
not enter the topic onto the database because they assume that
the NHSC team will enter it themselves soon (2).
A more accurate proxy of technologies that have made a
significant impact would be to elicit opinions from sufficient
numbers of health professionals, patients, and health service
managers, and commissioners and develop a list of recent tech-
nologies that have impacted on the delivery of care, patient ex-
periences and outcomes, and/or health service costs. Depending
on the remit given to an EAA system, their output could then
be compared with the most relevant opinion-based comparator.
Other outcome measures could include looking at the success
of NHSC topics notified to research funding organizations for
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prioritization for research funds, or for topics that progress
through screening program assessments into practice.
Other difficulties encountered in the study include a dif-
ficulty in establishing the licensing date of a specific clinical
indication in the European Union and the United Kingdom, re-
quired to ensure that the NHSC briefing came before licensing,
and linking past NHSC briefings to NICE appraisals topics. In
some cases the specific patient indication did not correspond ex-
actly between the NHSC topic and later NICE appraisal topic.
The objectivity of the authors as assessors of the NHSC sys-
tems and activity can also be questioned, and future plans for
evaluation of impact and accuracy could include the use of
independent assessors.
Relation to Other Literature: Comparative Strengths and Weaknesses
It is tempting to compare sensitivities and positive predictive
values found by different evaluations, but this may not be appro-
priate. Some EAA agencies are more reactive in their identifica-
tion processes, reacting to individual pharmaceuticals notified
to them by clinicians. This is in contrast to the NHSC which is
proactive in seeking out all pharmaceuticals in company devel-
opment pipelines. Being proactive is likely to reduce positive
predictive value, whilst being reactive should increase positive
predictive value.
Our estimated sensitivity is at the higher end of the range
estimated by Simpson et al. and higher than that of Douw and
Vondeling. However Simpson et al. were specifically investigat-
ing the accuracy of NHSC prioritization processes, and Douw
and Vondeling the completeness of expert identification and
the accuracy of expert prediction of impact. Our evaluation as-
sesses the accuracy of NHSC identification as well as filtration
processes over time. Our estimated positive predictive value of
0.39 (95 percent CI, 0.36 to 0.43), is higher than that found by
Simpson et al., but lower than that of Douw and Vondeling. But
again the systems being evaluated differ.
Policy Implications of the Findings
Given the legislative context of the NHSC and regulations
around the adoption and use of emerging technologies in the
English health service, is it ever possible for the NHSC (or other
EAA systems) to be 100 percent complete in its identification
processes and 100 percent accurate in the application of filtra-
tion criteria? Our opinion after working in this field for over 12
years, is no. The only safe method of identifying every possible
significant topic would be to require manufacturers to notify the
health service or EAA system of every development. However
the number of topics likely to make a significant impact will be
a sub-set of the total, and identifying those will require resource
intensive investigation and filtration, and the application of cri-
teria at some stage in the selection process for more detailed
technology assessment and appraisal, and issuance of guidance.
Given the current context, is missing 7.8 percent of emerg-
ing pharmaceuticals adequate for the NHSC and its funders and
customers? This is only something that can be decided by the
funders and other policy makers and decision makers in the
health service.
CONCLUSIONS
We have evaluated the accuracy of the identification and filtra-
tion stages of the NHSC and have shown that the NHSC fared
well with regards to sensitivity, but not so well with positive pre-
dictive value. Reassuringly, the level of missed pharmaceuticals
is small when compared with the topics considered important
enough to be referred to NICE for appraisal, and to the top-
ics identified and reported by EuroScan International Network
member agencies. However, the false positive rate of 60 percent
may indicate that the filtration criteria used could be tightened
for increased efficiency. Future evaluations of EAA systems
should include an element of external review and explore the
level of accuracy acceptable to funders and customers of such
systems.
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